SURVYR

PRME

Prime Medicine, Inc.
$4.35
+$0.74 (20.50%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-48%-32%-17%-1%+15%Oct 2025Oct 2026Apr 202652w high $5.6252w low $2.67
PRMESPY
Wall St. Highest PT $11.00 (+152.9%) Wall St. Avg PT $7.11 (+63.5%)
$3$5$7$9$11POC $3Hi $11Avg $7
Underwater Drawdown %Max DD -47.6%Current -15.5%
0.0%-47.6%
Relative Strength vs SPY-29.1% vs SPYUnderperforming
+66%0%-66%
1W
+$0.43 (10.97%)
1M
+$1.45 (50.00%)
3M
+$1.26 (40.78%)
6M
+$0.66 (17.89%)
YTD
+$0.88 (25.36%)
1Y
−$0.80 (15.53%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$4.35
Average target$7.11
+$2.76 (+63.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$4.25
Median$7.11
High$11.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-09-25 · Chardan Capital reiterated Buy on PRME
Reiterated
2026-08-25 · Chardan Capital reiterated Buy on PRME
Initiated
2026-08-19 · BMO Capital started covering PRME at Outperform
Reiterated
2026-08-10 · HC Wainwright & Co. reiterated Buy on PRME
Upgrade
2026-06-29 · HC Wainwright & Co. upgraded PRME from Neutral to Buy
Initiated
2026-03-12 · Oppenheimer started covering PRME at Outperform
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$691.0M
P/E (next 12 months, estimated)-4.3
52-week range$2.67 – $5.62
Revenue growth (latest quarter vs a year ago)+3.5%
Dividend yieldNo dividend
Average analyst price target$7.11 (+64%)

What they do

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for PRME yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PRME earningsNext report in 9 days
Next report · quarter Sep 2026
Fri Nov 6, 2026Before the open
EPS consensus-$0.23 range -$0.28–-$0.19
Revenue consensus$1.1M 11 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.24est -$0.26+6.0%Above estimates
May 7, 2026-$0.28est -$0.25−12.6%Below estimates
Mar 3, 2026-$0.24est -$0.26+6.9%Above estimates
Nov 7, 2025-$0.32est -$0.25−29.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:14:21 ET
24-1125-0225-0525-0825-1126-0326-0526-08-0.440.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.2M+3.5%
2026-03-31$856.0K–
2025-12-31$838.0K–
2025-09-30$1.2M–
2025-06-30$1.1M–

News & catalysts

More news
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Zacks · Oct 12
Canadian Investment Regulatory Organization Trade Resumption - PRME
CNW Group · Oct 05
Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT Newswires · Oct 05
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
GlobeNewswire · Oct 05
Canadian Investment Regulatory Organization Trading Halt - PRME
CNW Group · Sep 30
Rating changes
Reiterated
2026-09-25 · Chardan Capital reiterated Buy on PRME
Reiterated
2026-08-25 · Chardan Capital reiterated Buy on PRME
Initiated
2026-08-19 · BMO Capital started covering PRME at Outperform
Reiterated
2026-08-10 · HC Wainwright & Co. reiterated Buy on PRME
Upgrade
2026-06-29 · HC Wainwright & Co. upgraded PRME from Neutral to Buy
Initiated
2026-03-12 · Oppenheimer started covering PRME at Outperform

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 18:14:21 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026